STAT's Washington Correspondent John Wilkerson joins us to discuss the first round of drug pricing negotiations under the Inflation Reduction Act, which will wrap up by September 1. We also cover the latest news in the life sciences including the merger of AI drug development companies Recursion Pharmaceuticals and Exscientia, Novo Nordisk's decision to paus ... Show More
Jul 16
409: Predicting biotech clinical trials & a new Alzheimer's drug controversy
On this week’s episode of "The Readout LOUD": The Kalshi prediction markets are coming for biotech, plus the controversy over an experimental Alzheimer’s disease treatment from Biogen. Kalshi, the maker of prediction markets, announced this week that it is expanding into biotech. ... Show More
35m 32s
May 2023
Ozempic the Anti-Addiction Drug, Age of Streaming Mergers, & Bezos's Boat
Episode 65: Neal and Toby discuss the increasing buzz around potent weight loss drugs with Pfizer's oral version and Ozempic's anti-addiction side effects. Then, Showtime merges with Paramount+, Max absorbs Discovery+, and Disney+ wants to include Hulu. Are we entering the age of ... Show More
28m 43s
May 2025
Fed Decision On Deck… And Novo Nordisk Gears Up To Report 5/6/25
<p>Another key Fed decision on deck, as the recent stock market bounce loses steam. What to expect from Fed Chair Jerome Powell, and what it will mean for the market’s next move. Plus Earnings season in full swing, and Wegovy-maker Novo Nordisk is ready to report. Why one top hea ... Show More
43m 52s